Takeda's Dengue Vaccine Recommended by World Health Organiza

Experts Reviewed Data from QDENGA’s Clinical Program Across 19 Phase 1, 2 and 3 Trials with More Than 28,000 ParticipantsWHO Will Consider the SAGE Recommendation and Provide Final Guidance on the Use of QDENGA in Public Vaccination Programs in the Coming MonthsDengue Poses a Significant and Growing Public Health Bu...

Related Keywords

Sri Lanka , United States , Colombia , Philippines , Osaka , Japan , Nicaragua , Dominican Republic , Argentina , Indonesia , Thailand , Brazil , Panama , Japanese , America , Maiko Miura , Gary Dubin , Strategic Advisory Group Of Experts , Exchange Commission , Clinical Program , Takeda Pharmaceutical Company Limited , World Health Organization , European Union Eu Member States , Public Health Burden To People Living , Data Monitoring Committee , Experts Reviewed Data , Program Across , More Than , Provide Final Guidance , Public Vaccination Programs , Growing Public Health Burden , People Living , Strategic Advisory Group , Dengue Tetravalent Vaccine , Latin America , Global Vaccine Business Unit , Dengue Efficacy Study , European Union , Member States , Product Characteristics , Annual Report , Published March , Tetravalent Dengue Vaccine Candidate , Northern European Conference , Travel Medicine , Retrieved October , Tetravalent Dengue Vaccine , Healthy Children , Retrieved July , Health Organization , Technical Report Series , What You Need , Published April ,